摘要
Abstract
Systemic lupus erythematosus(SLE)is a classic systemic autoimmune disease whose patho-genesis primarily involves immune dysregulation,loss of self-tolerance,and abnormal activation of immune cells,with T-cell imbalance and aberrant activation playing a critical role.Helper T cell 17(Th17),a major subset of CD4+T cells,consists of pathogenic and non-pathogenic subpopulations.Its homeostatic imbalance has been implicated in the pathological progression of various autoimmune disorders,including spondyloarthritis and rheumatoid arthritis.In SLE,Th 17 cells exert pro-inflammatory effects by secreting effector cytokines such as interleukin-17(IL-17)and IL-22.However,their precise regulatory networks remain incompletely under-stood.Current research highlights multiple regulatory mechanisms,including retinoic acid receptor-related or-phan receptor γt(RORγt)transcription,the IL-23/STAT3 signaling pathway,and the endothelial protein C receptor(EPCR)pathway,while emerging mechanisms such as epigenetic modifications require further explo-ration.Therapeutic agents targeting the Th 17 pathway,such as IL-17 inhibitors(e.g.secukinumab)and IL-12/23 inhibitors(e.g.ustekinumab),have demonstrated efficacy in animal models and clinical studies,though with individual variability and potential risks.Conventional drugs(e.g.hydroxychloroquine,mycophe-nolate mofetil)and novel therapies(e.g.JAK inhibitors,type Ⅰ interferon antibodies,mesenchymal stem cells)may also displayed therapeutic benefits by modulating Th 17 cell differentiation and function.This review summarizes the role of Th17 cells in the pathological mechanism of SLE,as well as the current research ad-vances and the potential clinical applications of targeting this pathway in SLE treatment.关键词
系统性红斑狼疮/Th17细胞/致病性调控/靶向药物Key words
systemic lupus erythematosus/Th17 cells/pathogenic regulation/targeted drugs
